Polymorphs, Particle Size, and a Pandemic: Development of a Scalable Crystallization Process for Molnupiravir, an Antiviral for the Treatment of COVID-19
Molnupiravir is a small-molecule active pharmaceutical ingredient (API) prodrug of a nucleoside analog that was demonstrated to be efficacious for the treatment of patients with COVID-19. Early in the pandemic, Merck & Co. Inc. partnered with Ridgeback Biotherapeutics to accelerate the developme...
Saved in:
Published in | Organic process research & development Vol. 27; no. 11; pp. 2100 - 2110 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
American Chemical Society
17.11.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Molnupiravir is a small-molecule active pharmaceutical ingredient (API) prodrug of a nucleoside analog that was demonstrated to be efficacious for the treatment of patients with COVID-19. Early in the pandemic, Merck & Co. Inc. partnered with Ridgeback Biotherapeutics to accelerate the development of a manufacturing process for the drug in anticipation of high global demand for the treatment. It was essential to quickly establish a robust manufacturing process, as well as a rigorous physical attribute control strategy, to enable rapid delivery of metric tons of molnupiravir. Given the drug load of >50% (w/w) API in the formulation, there was high potential for the physical attributes to have a strong effect on drug product performance. Molnupiravir can also exist as multiple polymorphs and has the potential for wide variations in particle size. To address these challenges, we performed extensive derisking of these attributes with respect to the impact on drug product performance and were ultimately able to demonstrate the acceptability of a wide range of API physical attributes. In parallel, we strategically designed a scalable crystallization process that consistently delivered drug substance within our derisked range of attributes, across multiple manufacturing sites and scales. Thus, we were able to demonstrate that the API’s physical attributes did not affect the drug product’s critical quality attributes or therapeutic efficacy, giving our multiple manufacturing sites greater flexibility to deliver metric tons of molnupiravir to patients in need. |
---|---|
AbstractList | Molnupiravir is a small-molecule active pharmaceutical ingredient (API) prodrug of a nucleoside analog that was demonstrated to be efficacious for the treatment of patients with COVID-19. Early in the pandemic, Merck & Co. Inc. partnered with Ridgeback Biotherapeutics to accelerate the development of a manufacturing process for the drug in anticipation of high global demand for the treatment. It was essential to quickly establish a robust manufacturing process, as well as a rigorous physical attribute control strategy, to enable rapid delivery of metric tons of molnupiravir. Given the drug load of >50% (w/w) API in the formulation, there was high potential for the physical attributes to have a strong effect on drug product performance. Molnupiravir can also exist as multiple polymorphs and has the potential for wide variations in particle size. To address these challenges, we performed extensive derisking of these attributes with respect to the impact on drug product performance and were ultimately able to demonstrate the acceptability of a wide range of API physical attributes. In parallel, we strategically designed a scalable crystallization process that consistently delivered drug substance within our derisked range of attributes, across multiple manufacturing sites and scales. Thus, we were able to demonstrate that the API’s physical attributes did not affect the drug product’s critical quality attributes or therapeutic efficacy, giving our multiple manufacturing sites greater flexibility to deliver metric tons of molnupiravir to patients in need. |
Author | Mora, Jeff Poirier, Marc Stone, Kevin Lee, Ivan H. Luo, Hanlin Lowinger, Michael B. Masiuk, Tina Zompa, Michael A. Brito, Gilmar Xu, Yingju Brunskill, Andrew P. J. Bernardoni, Frank Ward, Michael D. Gmitter, Andrew J. Patel, Sanjaykumar Fier, Patrick S. Ni, Tong Tarabokija, James Okoh, Grace A. Zhang, Yongqian Tan, Melissa Liu, Jiaying Newman, Justin A. Zheng, Michelle Mahmood, Tariq Bothe, Jameson R. Bade, Rachel Sirota, Eric |
AuthorAffiliation | Analytical Research and Development Small Molecule Science and Technology Regulatory Affairs CMC Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc Process Research and Development |
AuthorAffiliation_xml | – name: Small Molecule Science and Technology – name: Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc – name: Process Research and Development – name: Analytical Research and Development – name: Regulatory Affairs CMC |
Author_xml | – sequence: 1 givenname: Rachel orcidid: 0000-0002-5384-9687 surname: Bade fullname: Bade, Rachel email: Rachel.Bade@merck.com organization: Process Research and Development – sequence: 2 givenname: Jameson R. orcidid: 0000-0002-1753-0994 surname: Bothe fullname: Bothe, Jameson R. email: Jameson.Bothe@merck.com organization: Analytical Research and Development – sequence: 3 givenname: Eric orcidid: 0000-0002-6205-0295 surname: Sirota fullname: Sirota, Eric organization: Process Research and Development – sequence: 4 givenname: Andrew P. J. surname: Brunskill fullname: Brunskill, Andrew P. J. organization: Analytical Research and Development – sequence: 5 givenname: Justin A. orcidid: 0000-0002-2498-1259 surname: Newman fullname: Newman, Justin A. organization: Analytical Research and Development – sequence: 6 givenname: Yongqian surname: Zhang fullname: Zhang, Yongqian organization: Analytical Research and Development – sequence: 7 givenname: Melissa surname: Tan fullname: Tan, Melissa organization: Analytical Research and Development – sequence: 8 givenname: Michelle surname: Zheng fullname: Zheng, Michelle organization: Process Research and Development – sequence: 9 givenname: Gilmar surname: Brito fullname: Brito, Gilmar organization: Process Research and Development – sequence: 10 givenname: Marc surname: Poirier fullname: Poirier, Marc organization: Process Research and Development – sequence: 11 givenname: Patrick S. orcidid: 0000-0002-6102-815X surname: Fier fullname: Fier, Patrick S. organization: Process Research and Development – sequence: 12 givenname: Yingju surname: Xu fullname: Xu, Yingju organization: Process Research and Development – sequence: 13 givenname: Michael D. surname: Ward fullname: Ward, Michael D. organization: Small Molecule Science and Technology – sequence: 14 givenname: Kevin orcidid: 0000-0003-3750-5072 surname: Stone fullname: Stone, Kevin organization: Process Research and Development – sequence: 15 givenname: Ivan H. surname: Lee fullname: Lee, Ivan H. organization: Process Research and Development – sequence: 16 givenname: Andrew J. surname: Gmitter fullname: Gmitter, Andrew J. organization: Small Molecule Science and Technology – sequence: 17 givenname: Frank surname: Bernardoni fullname: Bernardoni, Frank organization: Analytical Research and Development – sequence: 18 givenname: Michael A. orcidid: 0000-0003-2401-7846 surname: Zompa fullname: Zompa, Michael A. organization: Analytical Research and Development – sequence: 19 givenname: Hanlin surname: Luo fullname: Luo, Hanlin organization: Analytical Research and Development – sequence: 20 givenname: Sanjaykumar surname: Patel fullname: Patel, Sanjaykumar organization: Analytical Research and Development – sequence: 21 givenname: Tina surname: Masiuk fullname: Masiuk, Tina organization: Analytical Research and Development – sequence: 22 givenname: Jeff surname: Mora fullname: Mora, Jeff organization: Analytical Research and Development – sequence: 23 givenname: Tong surname: Ni fullname: Ni, Tong organization: Small Molecule Science and Technology – sequence: 24 givenname: Grace A. surname: Okoh fullname: Okoh, Grace A. organization: Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc – sequence: 25 givenname: James surname: Tarabokija fullname: Tarabokija, James organization: Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc – sequence: 26 givenname: Jiaying orcidid: 0000-0002-5376-5790 surname: Liu fullname: Liu, Jiaying organization: Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc – sequence: 27 givenname: Michael B. surname: Lowinger fullname: Lowinger, Michael B. organization: Analytical Research and Development – sequence: 28 givenname: Tariq surname: Mahmood fullname: Mahmood, Tariq organization: Regulatory Affairs CMC |
BookMark | eNp1kMtOwzAQRS1UJFpgz9If0BQ_SOqwq1peEohKPMQumjgTYeTakZ1Wav-EvyWhZclqrubeuRqdERk475CQC84mnAl-CTpOfBOqidSMiUwdkSFPBUtSlX0MOs2UTDKesRMyivGLMZZmXAzJ99Lb7cqH5jOO6RJCa7RF-mJ2OKbgKgrd0lW4MvqaLnCD1jcrdC31dWe9aLBQdvl52MYWrDU7aI13dBm8xhhp7QN98tatGxNgY0LfSWeuNZ0G-2u3n0hfA0L7Vzt_fn9YJDw_I8c12Ijnh3lK3m5vXuf3yePz3cN89piAUKxNKhSsLK9Q5Kme8lyXKbA8B1VPy0rJqcxUxWQ5xYxXQslMpiWWaV4JqVOBCrQ8JWzfq4OPMWBdNMGsIGwLzooebdGhLXq0xQFtdzLen_TOl18H1z34f_wH_IeBAw |
CitedBy_id | crossref_primary_10_1021_acs_cgd_4c00376 |
Cites_doi | 10.1208/pt050341 10.1016/j.cherd.2020.09.021 10.1002/jps.2600580802 10.1016/j.ijpharm.2011.02.048 10.1016/B978-0-12-802447-8.00028-5 10.1016/j.addr.2003.12.001 10.1016/S0169-409X(01)00100-4 10.1126/scitranslmed.abl7430 10.1016/j.ijrobp.2023.06.1110 10.1016/j.antiviral.2019.104597 10.1016/S0140-6736(22)02597-1 10.3851/IMP2229 10.1002/jps.2600520210 10.1021/acs.oprd.1c00400 10.1016/j.jbc.2021.100770 10.1016/S1359-6446(03)02832-0 10.1016/0378-5173(83)90111-4 10.1002/jps.2600520815 10.1128/AAC.47.1.244-254.2003 10.1016/j.dsx.2022.102396 10.1023/A:1016241927429 10.1056/NEJMoa2116044 10.1126/scitranslmed.abb5883 10.1021/acs.oprd.0c00166 10.1016/j.trsl.2019.12.002 10.1016/S0169-409X(01)00097-7 10.2174/0929867331666230726140736 10.1038/s41564-020-00835-2 10.3390/v7122934 10.1038/s41594-021-00651-0 |
ContentType | Journal Article |
Copyright | 2023 American Chemical Society |
Copyright_xml | – notice: 2023 American Chemical Society |
DBID | AAYXX CITATION |
DOI | 10.1021/acs.oprd.3c00268 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering Chemistry |
EISSN | 1520-586X |
EndPage | 2110 |
ExternalDocumentID | 10_1021_acs_oprd_3c00268 a197560553 |
GroupedDBID | -~X 123 4.4 55A 5VS 7~N AABXI ABFRP ABMVS ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 DU5 EBS ED~ F5P FDB GGK GNL IH9 JG~ RNS ROL UI2 VF5 VG9 W1F XKZ AAYXX ABJNI BAANH CITATION CUPRZ |
ID | FETCH-LOGICAL-a280t-de20bb4e295c719cb5a099a8f7bd837368d03b7e61d283635beb59d23c52e8ac3 |
IEDL.DBID | ACS |
ISSN | 1083-6160 |
IngestDate | Fri Dec 06 02:12:29 EST 2024 Mon Nov 20 03:50:13 EST 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | particle size molnupiravir antiviral crystallization covid-19 API polymorph |
Language | English |
License | https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a280t-de20bb4e295c719cb5a099a8f7bd837368d03b7e61d283635beb59d23c52e8ac3 |
ORCID | 0000-0003-3750-5072 0000-0002-5376-5790 0000-0002-6205-0295 0000-0003-2401-7846 0000-0002-5384-9687 0000-0002-6102-815X 0000-0002-2498-1259 0000-0002-1753-0994 |
PageCount | 11 |
ParticipantIDs | crossref_primary_10_1021_acs_oprd_3c00268 acs_journals_10_1021_acs_oprd_3c00268 |
PublicationCentury | 2000 |
PublicationDate | 2023-11-17 |
PublicationDateYYYYMMDD | 2023-11-17 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-17 day: 17 |
PublicationDecade | 2020 |
PublicationTitle | Organic process research & development |
PublicationTitleAlternate | Org. Process Res. Dev |
PublicationYear | 2023 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref6/cit6 ref3/cit3 ref27/cit27 ref18/cit18 Badawy S. (ref31/cit31) 2017 ref11/cit11 ref25/cit25 (ref33/cit33) 2019 ref16/cit16 ref29/cit29 ref32/cit32 ref23/cit23 ref14/cit14 ref8/cit8 ref5/cit5 ref2/cit2 ref34/cit34 ref28/cit28 Badawy S. I. F. (ref30/cit30) 2004; 5 ref20/cit20 ref17/cit17 ref10/cit10 ref26/cit26 ref19/cit19 ref21/cit21 ref12/cit12 ref15/cit15 ref22/cit22 ref13/cit13 ref4/cit4 ref1/cit1 ref24/cit24 ref7/cit7 |
References_xml | – ident: ref26/cit26 – volume: 5 start-page: 38 issue: 3 year: 2004 ident: ref30/cit30 publication-title: AAPS PharmSciTech doi: 10.1208/pt050341 contributor: fullname: Badawy S. I. F. – ident: ref28/cit28 doi: 10.1016/j.cherd.2020.09.021 – ident: ref17/cit17 doi: 10.1002/jps.2600580802 – ident: ref32/cit32 doi: 10.1016/j.ijpharm.2011.02.048 – start-page: 749 volume-title: Developing Solid Oral Dosage Forms year: 2017 ident: ref31/cit31 doi: 10.1016/B978-0-12-802447-8.00028-5 contributor: fullname: Badawy S. – ident: ref16/cit16 doi: 10.1016/j.addr.2003.12.001 – ident: ref24/cit24 – ident: ref18/cit18 doi: 10.1016/S0169-409X(01)00100-4 – ident: ref3/cit3 doi: 10.1126/scitranslmed.abl7430 – ident: ref10/cit10 doi: 10.1016/j.ijrobp.2023.06.1110 – ident: ref9/cit9 doi: 10.1016/j.antiviral.2019.104597 – ident: ref5/cit5 doi: 10.1016/S0140-6736(22)02597-1 – ident: ref13/cit13 doi: 10.3851/IMP2229 – ident: ref23/cit23 doi: 10.1002/jps.2600520210 – ident: ref25/cit25 doi: 10.1021/acs.oprd.1c00400 – ident: ref7/cit7 doi: 10.1016/j.jbc.2021.100770 – ident: ref22/cit22 doi: 10.1016/S1359-6446(03)02832-0 – volume-title: Handbook of Industrial Crystallization year: 2019 ident: ref33/cit33 – ident: ref20/cit20 doi: 10.1016/0378-5173(83)90111-4 – ident: ref19/cit19 doi: 10.1002/jps.2600520815 – ident: ref27/cit27 – ident: ref14/cit14 doi: 10.1128/AAC.47.1.244-254.2003 – ident: ref34/cit34 doi: 10.1016/j.dsx.2022.102396 – ident: ref15/cit15 doi: 10.1023/A:1016241927429 – ident: ref4/cit4 doi: 10.1056/NEJMoa2116044 – ident: ref1/cit1 doi: 10.1126/scitranslmed.abb5883 – ident: ref29/cit29 doi: 10.1021/acs.oprd.0c00166 – ident: ref8/cit8 doi: 10.1016/j.trsl.2019.12.002 – ident: ref21/cit21 doi: 10.1016/S0169-409X(01)00097-7 – ident: ref11/cit11 doi: 10.2174/0929867331666230726140736 – ident: ref2/cit2 doi: 10.1038/s41564-020-00835-2 – ident: ref12/cit12 doi: 10.3390/v7122934 – ident: ref6/cit6 doi: 10.1038/s41594-021-00651-0 |
SSID | ssj0005612 |
Score | 2.443025 |
Snippet | Molnupiravir is a small-molecule active pharmaceutical ingredient (API) prodrug of a nucleoside analog that was demonstrated to be efficacious for the... |
SourceID | crossref acs |
SourceType | Aggregation Database Publisher |
StartPage | 2100 |
Title | Polymorphs, Particle Size, and a Pandemic: Development of a Scalable Crystallization Process for Molnupiravir, an Antiviral for the Treatment of COVID-19 |
URI | http://dx.doi.org/10.1021/acs.oprd.3c00268 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ZS8NAEF48HtQHb_FmH_RBaGqym9O3Ei0qeECt-Bb2ChRLIk0r2H_iv3Wm3dLiAb7uZodldsJ8w8x8Q8gJMwnYUa4dX8jI8ROpHeljI3AQR4lxQwWnsNriPrxu-7cvwcuUJud7Bp9550JV9RLZELnCgCGeJ4ssgugbYVDampZzhDazGXMIh0LXpiR_k4COSFUzjmjGozTXxqOJqhERIRaSvNYHfVlXw580jf-47DpZtcCSNsaWsEHmTLFJltLJPLdNsjJDPbhFPh_LLoT9oOWqRh-t_dBWZ2hqVBSaClgsRpXzF3SmsIiWOWy14GGx5YqmvQ9Al92ubeaktu2AAhKmd2W3GGAa_73TQ5m0UeCkih5cErcBeNKnSZU7ik0fnm8uHS_ZJu3m1VN67dgxDY5gsdt3tGGulL5hSaAiL1EyEAA7RZxHUkP4y8NYu1xGJvQ0YBkAONLIINGMq4CZWCi-QxaKsjC7hBoPDgquhDG-7wqZmJx5OQsNDwOhA75HTkHDmf3NqmyUQWdehouo9syqfY-cTd42exuzdvz57f4_ZR6QZRw1j32IXnRIFvq9gTkCQNKXxyNL_AIDAN1q |
link.rule.ids | 314,780,784,2765,27076,27924,27925,56738,56788 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LTxRBEK4gHJADImrAZx_0YMLgdPf0PLiRUbIoIHEXw23Sr0mI64zZ2SWBf-K_pWrolY3RRK_V05VKdU3qq9QL4LXwBdpR7aJEmyxKCuMik1AjsMqzwsepxVtUbXGSDs6Sj-fqfAn4vBcGheiQU9cn8e-mC_B3PY2GIkpLcUN-D1YUbawkNFQO76o60pDgzCVGRWkcMpN_4kD-yHYL_mjBsRw8gC-_ROrrSb7tzqZm117_Nq3xv2TegPUAM9n-rV08hCXfbMJqOd_utglrC4MIH8HP03Z89b1FnXc77DRYExteXPsdphvHNBKbvo5-jy2UGbG2xqMhPjM1YLFycoVYczwOrZ0sNCEwxMXsuB03M0rqX15MiCfbb2hvxQSFpGOEoWw0r3kntuXnr4fvI148hrODD6NyEIWlDZEWeTyNnBexMYkXhbIZL6xRGkGozuvMOAyGZZq7WJrMp9whskG4Y7xRhRPSKuFzbeUTWG7axm8B8xwvamm190kSa1P4WvBapF6mSjslt-ENargKP11X9fl0wSsiktqroPZteDt_4urH7QyPv3779B95voLVwej4qDo6PPn0DO7TEnrqUOTZc1ieTmb-BUKVqXnZG-cNL7Hl1w |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9RAEJ8gJioPiAgBFdkHfTCh0O52-8HbpXjhQ_GSA8Jbs19NiEdLrnck8J_43zpT9uRiNNHX3e5kMjvb_W3mNzMAH7jL0Y8qG8RKp0GcaxvomBKBZZbmLkwMriK2xWlyeB4fX8rLBZCzXBhUokVJbRfEp1N9YytfYSDa68apMKIw9HbInsBTiT9bYnL1iuEjsyPxQc5M4MsoCX108k8S6E4y7dydNHe59F_CxS-1Ok7J993pRO-a-98qNv633iuw7OEm6z34xytYcPUqPC9mXd5WYWmuIOFr-DFoRnfXDdq-3WED71VseHXvdpiqLVM4WHd8-n02RzdiTYVTQ9xuSsRixfgOMedo5FM8mU9GYIiP2ddmVE8puH97NSaZrFdT_4oxKknTCEfZ2Yz7TmKLbxdHB0GUr8F5__NZcRj45g2B4lk4Cazjodax47k0aZQbLRWCUZVVqbb4KBZJZkOhU5dEFhEOwh7ttMwtF0Zylykj1mGxbmq3AcxFuFAJo5yL41Dp3FU8qnjiRCKVlWITPqKFS3_42rKLq_OopEEye-nNvgmfZttc3jzU8vjrt2_-UeY2PBsc9MsvR6cnb-EF9aKnRMUofQeLk_HUbSFimej3nX_-BKbK6Fo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polymorphs%2C+Particle+Size%2C+and+a+Pandemic%3A+Development+of+a+Scalable+Crystallization+Process+for+Molnupiravir%2C+an+Antiviral+for+the+Treatment+of+COVID-19&rft.jtitle=Organic+process+research+%26+development&rft.au=Bade%2C+Rachel&rft.au=Bothe%2C+Jameson+R.&rft.au=Sirota%2C+Eric&rft.au=Brunskill%2C+Andrew+P.+J.&rft.date=2023-11-17&rft.pub=American+Chemical+Society&rft.issn=1083-6160&rft.eissn=1520-586X&rft.volume=27&rft.issue=11&rft.spage=2100&rft.epage=2110&rft_id=info:doi/10.1021%2Facs.oprd.3c00268&rft.externalDocID=a197560553 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-6160&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-6160&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-6160&client=summon |